← All organizations

I-Mab Biopharma

For profitWebsite ↗

Also known as: I-Mab Biopharma | I-Mab Biopharma Co. Ltd. | I-Mab Biopharma HongKong Limited | I-Mab Biopharma US Limited

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Last known activity

Mar 30, 2023

Timeline

2010s

Jun 1, 2016
I-Mab Biopharma— Founded

Drugs by trial phase (18 distinct, 23 trials)

Phase 3 (6 own, 0 via acquisition)

Phase 2 (6 own, 0 via acquisition)

Phase 1 (5 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

atezolizumab

Indications

Studied for

Recent trials (27)

NCT04869501Lead sponsorN/A—
NCT05511350Lead sponsorN/A—
NCT05709093Lead sponsorPhase 3Mar 30, 2023
NCT05338580Lead sponsorPhase 2Dec 31, 2022
NCT05145907Lead sponsorPhase 2Dec 31, 2021
NCT04947033Lead sponsorPhase 1Dec 31, 2021
NCT05140824Lead sponsorPhase 1Dec 31, 2021
NCT05148533Lead sponsorPhase 1/Phase 2Dec 31, 2021
NCT05145907Study directorPhase 2Dec 31, 2021
NCT07187141CollaboratorPhase 1Nov 18, 2021
NCT05001347Lead sponsorPhase 2Oct 31, 2021
NCT04900818Lead sponsorPhase 1Jun 29, 2021
NCT04633057Lead sponsorPhase 3Jan 25, 2021
NCT04678921Lead sponsorPhase 1Dec 17, 2020
NCT04600817Lead sponsorPhase 2Nov 24, 2020

Details

Founded: Shanghai, CN Jun 1, 2016
Last known activity: Mar 30, 2023